The biological effects of ruxolitinib, a JAK1 and JAK2 inhibitor, on mesenchymal stromal cells (MSCs), isolated from salivary glands of both pSS patients and controls, have been recently evaluated in vitro. Here, JAK2 is linked to peeling skin syndrome.